{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma&page=5&q=uveal+melanoma",
    "query": {
      "q": "uveal melanoma",
      "condition": "Melanoma",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 203,
    "total_pages": 21,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma&page=6&q=uveal+melanoma&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma&page=4&q=uveal+melanoma&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T11:55:37.909Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01728051",
      "title": "Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Metastatic Liver Cancer",
        "Ocular Melanoma",
        "Cutaneous Melanoma"
      ],
      "interventions": [
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Percutaneous Hepatic Perfusion",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Delcath Systems Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-10-23",
      "last_synced_at": "2026-10-14T11:55:37.909Z",
      "location_count": 6,
      "location_summary": "Santa Monica, California • Englewood, Colorado • Tampa, Florida + 3 more",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Morristown",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01728051"
    },
    {
      "nct_id": "NCT02158520",
      "title": "Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Melanoma",
        "Mucosal Melanoma",
        "Stage IV Cutaneous Melanoma AJCC v6 and v7",
        "Stage IV Uveal Melanoma AJCC v7",
        "Unresectable Melanoma"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Academic and Community Cancer Research United",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2013-10-18",
      "completion_date": "2019-10-30",
      "has_results": true,
      "last_update_posted_date": "2020-01-21",
      "last_synced_at": "2026-10-14T11:55:37.909Z",
      "location_count": 13,
      "location_summary": "San Francisco, California • Jacksonville, Florida • Chicago, Illinois + 10 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Sioux City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02158520"
    },
    {
      "nct_id": "NCT02363283",
      "title": "Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Uveal Melanoma",
        "Stage IV Uveal Melanoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Glembatumumab Vedotin",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2015-09-16",
      "completion_date": "2018-07-02",
      "has_results": true,
      "last_update_posted_date": "2020-08-21",
      "last_synced_at": "2026-10-14T11:55:37.909Z",
      "location_count": 25,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Aurora, Colorado + 17 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02363283"
    },
    {
      "nct_id": "NCT03635632",
      "title": "C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Relapsed Neuroblastoma",
        "Refractory Neuroblastoma",
        "Relapsed Osteosarcoma",
        "Relapsed Ewing Sarcoma",
        "Relapsed Rhabdomyosarcoma",
        "Uveal Melanoma",
        "Phyllodes Breast Tumor"
      ],
      "interventions": [
        {
          "name": "C7R-GD2.CART cells",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "1 Year to 74 Years"
      },
      "enrollment_count": 94,
      "start_date": "2019-04-23",
      "completion_date": "2038-05-16",
      "has_results": false,
      "last_update_posted_date": "2026-07-06",
      "last_synced_at": "2026-10-14T11:55:37.909Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03635632"
    },
    {
      "nct_id": "NCT02273219",
      "title": "Trial of AEB071 in Combination With BYL719 in Patients With Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Uveal Melanoma"
      ],
      "interventions": [
        {
          "name": "AEB071",
          "type": "DRUG"
        },
        {
          "name": "BYL719",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2014-11-19",
      "completion_date": "2018-07-02",
      "has_results": false,
      "last_update_posted_date": "2023-08-15",
      "last_synced_at": "2026-10-14T11:55:37.909Z",
      "location_count": 3,
      "location_summary": "Miami, Florida • New York, New York",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02273219"
    },
    {
      "nct_id": "NCT00003022",
      "title": "Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors",
        "Intraocular Melanoma",
        "Lung Cancer",
        "Melanoma (Skin)",
        "Neuroblastoma",
        "Retinoblastoma",
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "iodine I 131 monoclonal antibody 3F8",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "3 Years and older"
      },
      "enrollment_count": null,
      "start_date": "1997-04",
      "completion_date": "2005-01",
      "has_results": false,
      "last_update_posted_date": "2013-07-03",
      "last_synced_at": "2026-10-14T11:55:37.909Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003022"
    },
    {
      "nct_id": "NCT03922880",
      "title": "Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Uveal Melanoma"
      ],
      "interventions": [
        {
          "name": "ADI PEG20",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2019-04-16",
      "completion_date": "2023-01-20",
      "has_results": false,
      "last_update_posted_date": "2025-05-15",
      "last_synced_at": "2026-10-14T11:55:37.909Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03922880"
    },
    {
      "nct_id": "NCT05812027",
      "title": "A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Head and Neck Cancer",
        "Cervical Cancer",
        "Non Small Cell Lung Cancer",
        "HPV16 Related Cancers",
        "Sarcoma",
        "Uveal Melanoma",
        "NUT Carcinoma"
      ],
      "interventions": [
        {
          "name": "Tumor and HLA Profiling",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "TScan Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1150,
      "start_date": "2023-06-26",
      "completion_date": "2027-01-14",
      "has_results": false,
      "last_update_posted_date": "2025-11-17",
      "last_synced_at": "2026-10-14T11:55:37.909Z",
      "location_count": 21,
      "location_summary": "Scottsdale, Arizona • San Diego, California • New Haven, Connecticut + 17 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05812027"
    },
    {
      "nct_id": "NCT04082962",
      "title": "Dexamethasone Implant for Retinal Detachment in Uveal Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Exudative Retinal Detachment and Uveal Melanoma"
      ],
      "interventions": [
        {
          "name": "Dexamethasone intravitreal implant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ivana K. Kim",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2018-12-11",
      "completion_date": "2023-12-07",
      "has_results": false,
      "last_update_posted_date": "2025-12-17",
      "last_synced_at": "2026-10-14T11:55:37.909Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04082962"
    },
    {
      "nct_id": "NCT06022029",
      "title": "A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Triple Negative Breast Cancer",
        "Diffuse Large B Cell Lymphoma",
        "Follicular Lymphoma",
        "Lymphoma, Non-Hodgkin",
        "Mantle Cell Lymphoma",
        "Bladder Cancer",
        "Uveal Melanoma, Recurrent",
        "Cervix Cancer",
        "Carcinoma in Situ",
        "Head and Neck Squamous Cell Carcinoma",
        "Skin Cancer",
        "Metastatic Cancer",
        "Tumor, Solid",
        "Tumor Recurrence"
      ],
      "interventions": [
        {
          "name": "ONM-501",
          "type": "DRUG"
        },
        {
          "name": "Cemiplimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OncoNano Medicine, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 168,
      "start_date": "2023-10-13",
      "completion_date": "2026-08-29",
      "has_results": false,
      "last_update_posted_date": "2025-12-24",
      "last_synced_at": "2026-10-14T11:55:37.909Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Tamarac, Florida • Canton, Ohio + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tamarac",
          "state": "Florida"
        },
        {
          "city": "Canton",
          "state": "Ohio"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06022029"
    }
  ]
}